rs121964969
Positions:
Variant summary
Our verdict is Pathogenic. Variant got 14 ACMG points: 14P and 0B. PM1PM5PP3_ModeratePP5_Very_Strong
The NM_000071.3(CBS):c.797G>A(p.Arg266Lys) variant causes a missense change. In-silico tool predicts a pathogenic outcome for this variant. Variant has been reported in ClinVar as Likely pathogenic (★★). Another variant affecting the same amino acid position, but resulting in a different missense (i.e. R266G) has been classified as Likely pathogenic.
Frequency
Genomes: not found (cov: 4)
Exomes 𝑓: 0.000015 ( 0 hom. )
Consequence
CBS
NM_000071.3 missense
NM_000071.3 missense
Scores
8
7
4
Clinical Significance
Conservation
PhyloP100: 6.85
Genes affected
CBS (HGNC:1550): (cystathionine beta-synthase) The protein encoded by this gene acts as a homotetramer to catalyze the conversion of homocysteine to cystathionine, the first step in the transsulfuration pathway. The encoded protein is allosterically activated by adenosyl-methionine and uses pyridoxal phosphate as a cofactor. Defects in this gene can cause cystathionine beta-synthase deficiency (CBSD), which can lead to homocystinuria. This gene is a major contributor to cellular hydrogen sulfide production. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Feb 2016]
Genome browser will be placed here
ACMG classification
Classification made for transcript
Verdict is Pathogenic. Variant got 14 ACMG points.
PM1
In a helix (size 12) in uniprot entity CBS_HUMAN there are 9 pathogenic changes around while only 0 benign (100%) in NM_000071.3
PM5
Other missense variant is known to change same aminoacid residue: Variant chrnull-null-null-null is described in UniProt as null.
PP3
MetaRNN computational evidence supports a deleterious effect, 0.912
PP5
Variant 21-43063931-C-T is Pathogenic according to our data. Variant chr21-43063931-C-T is described in ClinVar as [Likely_pathogenic]. Clinvar id is 125.Status of the report is criteria_provided_multiple_submitters_no_conflicts, 2 stars. Variant chr21-43063931-C-T is described in Lovd as [Pathogenic].
Transcripts
RefSeq
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | MANE | Protein | UniProt |
---|---|---|---|---|---|---|---|---|
CBS | NM_000071.3 | c.797G>A | p.Arg266Lys | missense_variant | 9/17 | ENST00000398165.8 | NP_000062.1 |
Ensembl
Gene | Transcript | HGVSc | HGVSp | Effect | #exon/exons | TSL | MANE | Protein | Appris | UniProt |
---|---|---|---|---|---|---|---|---|---|---|
CBS | ENST00000398165.8 | c.797G>A | p.Arg266Lys | missense_variant | 9/17 | 1 | NM_000071.3 | ENSP00000381231.4 |
Frequencies
GnomAD3 genomes Cov.: 4
GnomAD3 genomes
Cov.:
4
GnomAD3 exomes AF: 0.00000801 AC: 2AN: 249680Hom.: 0 AF XY: 0.00000740 AC XY: 1AN XY: 135184
GnomAD3 exomes
AF:
AC:
2
AN:
249680
Hom.:
AF XY:
AC XY:
1
AN XY:
135184
Gnomad AFR exome
AF:
Gnomad AMR exome
AF:
Gnomad ASJ exome
AF:
Gnomad EAS exome
AF:
Gnomad SAS exome
AF:
Gnomad FIN exome
AF:
Gnomad NFE exome
AF:
Gnomad OTH exome
AF:
GnomAD4 exome AF: 0.0000146 AC: 3AN: 205802Hom.: 0 Cov.: 0 AF XY: 0.0000183 AC XY: 2AN XY: 109370
GnomAD4 exome
AF:
AC:
3
AN:
205802
Hom.:
Cov.:
0
AF XY:
AC XY:
2
AN XY:
109370
Gnomad4 AFR exome
AF:
Gnomad4 AMR exome
AF:
Gnomad4 ASJ exome
AF:
Gnomad4 EAS exome
AF:
Gnomad4 SAS exome
AF:
Gnomad4 FIN exome
AF:
Gnomad4 NFE exome
AF:
Gnomad4 OTH exome
AF:
GnomAD4 genome Cov.: 4
GnomAD4 genome
Cov.:
4
Alfa
AF:
Hom.:
EpiCase
AF:
EpiControl
AF:
ClinVar
Significance: Pathogenic/Likely pathogenic
Submissions summary: Pathogenic:7
Revision: criteria provided, multiple submitters, no conflicts
LINK: link
Submissions by phenotype
Classic homocystinuria Pathogenic:2
Likely pathogenic, criteria provided, single submitter | clinical testing | Counsyl | Oct 09, 2017 | - - |
Likely pathogenic, criteria provided, single submitter | clinical testing | Baylor Genetics | Feb 23, 2024 | - - |
Homocystinuria, pyridoxine-responsive Pathogenic:1
Pathogenic, no assertion criteria provided | literature only | OMIM | Dec 01, 1997 | - - |
Familial thoracic aortic aneurysm and aortic dissection Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Ambry Genetics | Jun 16, 2017 | The p.R266K pathogenic mutation (also known as c.797G>A), located in coding exon 7 of the CBS gene, results from a G to A substitution at nucleotide position 797. The arginine at codon 266 is replaced by lysine, an amino acid with highly similar properties. This mutation has been reported in the homozygous state in several Norwegian patients with homocystinuria (Kim CE et al. Hum. Mol. Genet. 1997;6:2213-21). It has also been identified in the heterozygous state in two individuals with homocystinuria in whom the second allele is unknown (Kim CE et al. Hum. Mol. Genet. 1997;6:2213-21; Moat SJ et al. Hum. Mutat. 2004;23:206). Multiple labs have shown that this alteration leads to reduced enzyme activity and decreased stability of the CBS protein in vitro (e.g., Chen X et al. Hum. Mutat. 2006;27:474-82; Singh S et al. J. Inorg. Biochem. 2009;103:689-97; Kozich V et al. Hum. Mutat. 2010;31:809-19; Kopecká J et al. J. Inherit. Metab. Dis. 2011;34:39-48; Melenovská P et al. J. Inherit. Metab. Dis. 2015;38:287-94). In addition, a transgenic mouse model expressing this alteration exhibits reduced CBS enzyme activity, increased proteasomal degradation of the CBS protein, and elevated levels of total homocysteine in serum (Gupta S et al. Hum. Mutat. 2017;38:863-869). Based on the supporting evidence, this alteration is interpreted as a disease-causing mutation. - |
HYPERHOMOCYSTEINEMIA, THROMBOTIC, CBS-RELATED Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Labcorp Genetics (formerly Invitae), Labcorp | Aug 29, 2023 | For these reasons, this variant has been classified as Pathogenic. Experimental studies have shown that this missense change affects CBS function (PMID: 9361025, 16619244, 20506325, 22267502, 22333527, 22612060, 22738154). Advanced modeling of protein sequence and biophysical properties (such as structural, functional, and spatial information, amino acid conservation, physicochemical variation, residue mobility, and thermodynamic stability) performed at Invitae indicates that this missense variant is expected to disrupt CBS protein function. ClinVar contains an entry for this variant (Variation ID: 125). This missense change has been observed in individuals with pyridoxine-responsive CBS deficiency (PMID: 9361025). This variant is present in population databases (rs121964969, gnomAD 0.002%). This sequence change replaces arginine, which is basic and polar, with lysine, which is basic and polar, at codon 266 of the CBS protein (p.Arg266Lys). - |
not provided Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | GeneDx | Jan 13, 2020 | Published functional studies demonstrate a damaging effect (Kim et al., 1997; Kozich et al., 2010; Majtan et al., 2012); Reported as pathogenic/likely pathogenic in ClinVar but additional evidence is not available (SCV000543517.2, SCV000738475.2, SCV000790684.1; Landrum et al., 2016); Not observed at a significant frequency in large population cohorts (Lek et al., 2016); In silico analysis, which includes protein predictors and evolutionary conservation, supports a deleterious effect; This variant is associated with the following publications: (PMID: 31301157, 9361025, 19232736, 11343305, 12686134, 15192637, 16619244, 20490928, 25331909, 28488385, 22333527, 20506325, 22267502, 22738154, 22612060, 14722927) - |
Homocystinuria Pathogenic:1
Pathogenic, criteria provided, single submitter | clinical testing | Women's Health and Genetics/Laboratory Corporation of America, LabCorp | Nov 15, 2022 | Variant summary: CBS c.797G>A (p.Arg266Lys) results in a conservative amino acid change located in the pyridoxal-phosphate dependent enzyme domain (IPR001926) of the encoded protein sequence. Three of five in-silico tools predict a damaging effect of the variant on protein function. The variant allele was found at a frequency of 8e-06 in 249680 control chromosomes (gnomAD) and c.797G>A has been reported in the literature in multiple individuals affected with Homocystinuria (e.g. Guttormsen_2001, Moat_2004). These data indicate that the variant is very likely to be associated with disease. The variant is responsive to pyridoxine therapy (Guttormsen_2001). The effect of this variant on its enzymatic function has been characterized in detail. Several in vitro experiments suggest that this variant moderately reduces enzymatic activity (e.g. Chen _2006, Kozich _2010). Furthermore, in transgenic mice expressing the p.R266K variant, Gupta et al demonstrated that the variant results in increased proteasomal degradation of the enzyme and found that CBS activity is reduced to only 2% of that in livers expressing wild-type human CBS (Gupta_2017). Four clinical diagnostic laboratories have submitted clinical-significance assessments for this variant to ClinVar after 2014. All laboratories classified the variant as either pathogenic (n=3) or likely pathogenic (n=1). Based on the evidence outlined above, the variant was classified as pathogenic. - |
Computational scores
Source:
Name
Calibrated prediction
Score
Prediction
AlphaMissense
Uncertain
BayesDel_addAF
Pathogenic
D
BayesDel_noAF
Pathogenic
CADD
Pathogenic
DANN
Uncertain
DEOGEN2
Pathogenic
D;D;D;D
Eigen
Uncertain
Eigen_PC
Uncertain
FATHMM_MKL
Pathogenic
D
LIST_S2
Pathogenic
.;.;.;D
M_CAP
Uncertain
D
MetaRNN
Pathogenic
D;D;D;D
MetaSVM
Pathogenic
D
MutationAssessor
Benign
L;L;L;L
PrimateAI
Uncertain
T
PROVEAN
Uncertain
D;D;D;D
REVEL
Pathogenic
Sift
Benign
T;T;T;T
Sift4G
Benign
T;T;T;T
Polyphen
P;P;P;P
Vest4
MVP
MPC
0.95
ClinPred
D
GERP RS
Varity_R
gMVP
Splicing
Name
Calibrated prediction
Score
Prediction
SpliceAI score (max)
Details are displayed if max score is > 0.2
Find out detailed SpliceAI scores and Pangolin per-transcript scores at